MICOY Therapeutics
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
760 Parkside Ave Ste 206, Brooklyn, New ...Website
www.micoytherapeutics.comRevenue
<$5 MillionIndustry
About MICOY Therapeutics
Is MICOY Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
MICOY Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if MICOY Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at MICOY Therapeutics
Earning: See what the market has to say on MICOY Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if MICOY Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when MICOY Therapeutics launches new products
Funding: Get notified immidiatlly once MICOY Therapeutics has new funding data
Check out if MICOY Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
MICOY Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MICOY Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MICOY Therapeutics.
MICOY Therapeutics News & Media
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MICOY Therapeutics
MICOY Therapeutics is dedicated to developing innovative therapeutics that target harmful autoantibodies, which can inhibit immune responses and increase vulnerability to infections and cancer. Their first-in-class decoy therapies aim to block these autoantibodies while being inert to avoid severe side effects. The company focuses on addressing the... Read More